PriceTargets.com logo

NASDAQ:SCYX - SCYNEXIS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.50
  • Forecasted Upside: 1,031.58 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.90 As of 05/25/2022 01:00 AM ET
▼ -0.03 (-1.55%)

This chart shows the closing price for SCYX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SCYNEXIS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCYX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCYX

Analyst Price Target is $21.50
▲ +1,031.58% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for SCYNEXIS in the last 3 months. The average price target is $21.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,031.58% upside from the last price of $1.90.

This chart shows the closing price for SCYX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in SCYNEXIS. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022HC WainwrightLower Price Target$14.00 ➝ $8.00High
3/31/2022HC WainwrightLower Price TargetBuy$20.00 ➝ $14.00Medium
8/24/2021Brookline Capital ManagementReiterated RatingBuyLow
6/30/2021HC WainwrightReiterated RatingBuy$20.00Medium
6/7/2021AegisLower Price TargetBuy$40.00 ➝ $35.00Low
6/3/2021HC WainwrightReiterated RatingBuyMedium
5/18/2021HC WainwrightReiterated RatingBuyHigh
4/12/2021AegisLower Price TargetBuy$45.00 ➝ $40.00High
2/17/2021Maxim GroupBoost Price TargetBuy$17.00 ➝ $22.00Low
2/15/2021AegisReiterated RatingBuyHigh
1/22/2021GuggenheimInitiated CoverageBuy$25.00High
1/5/2021Cantor FitzgeraldInitiated CoverageOverweight$30.00N/A
12/28/2020HC WainwrightLower Price TargetBuy$35.00 ➝ $20.00N/A
12/23/2020Maxim GroupReiterated RatingBuy$17.00N/A
11/6/2020Maxim GroupReiterated RatingBuy$15.00High
8/11/2020LADENBURG THALM/SH SHReiterated RatingBuy$25.00High
8/10/2020Needham & Company LLCInitiated CoverageBuy$50.00High
7/15/2020Needham & Company LLCReiterated RatingBuy$50.00High
5/31/2020AegisReiterated RatingBuy$45.00High
5/19/2020HC WainwrightReiterated RatingBuy$35.00Medium
5/11/2020Needham & Company LLCReiterated RatingBuy$50.00Low
4/23/2020AegisBoost Price TargetBuy$40.00 ➝ $45.00High
4/22/2020Maxim GroupReiterated RatingBuy$40.00Medium
4/22/2020HC WainwrightReiterated RatingBuy$35.00High
4/21/2020Needham & Company LLCInitiated CoverageBuy$50.00High
3/12/2020Maxim GroupReiterated RatingBuy$40.00High
2/14/2020LADENBURG THALM/SH SHReiterated RatingBuyHigh
1/9/2020HC WainwrightReiterated RatingBuy$35.00Low
1/9/2020LADENBURG THALM/SH SHReiterated RatingBuy$60.00Medium
12/16/2019HC WainwrightReiterated RatingBuy$35.00Low
11/7/2019Needham & Company LLCReiterated RatingBuy$50.00Low
11/5/2019LADENBURG THALM/SH SHReiterated RatingBuy$60.00Low
10/18/2019Needham & Company LLCSet Price TargetBuy$50.00Low
8/19/2019Brookline Capital ManagementReiterated RatingBuyHigh
8/12/2019Needham & Company LLCReiterated RatingBuy$50.00Low
7/31/2019AegisInitiated CoverageBuyMedium
7/24/2019Maxim GroupSet Price TargetBuy$40.00Low
5/24/2019LADENBURG THALM/SH SHSet Price TargetBuy$60.00Low
5/12/2019Needham & Company LLCReiterated RatingBuy$50.00Medium
4/16/2019Needham & Company LLCReiterated RatingBuy$50.00Medium
3/18/2019Maxim GroupReiterated RatingBuy$40.00High
1/4/2019Brookline Capital ManagementReiterated RatingBuyHigh
11/13/2018Maxim GroupSet Price TargetBuy$40.00Low
10/23/2018HC WainwrightSet Price TargetBuy$50.00Low
10/16/2018Maxim GroupLower Price TargetBuy ➝ Buy$60.00 ➝ $40.00High
8/17/2018HC WainwrightSet Price TargetBuy$50.00Low
8/10/2018Needham & Company LLCSet Price TargetBuy$50.00Medium
8/10/2018Maxim GroupReiterated RatingBuy$60.00High
7/11/2018HC WainwrightSet Price TargetBuy$50.00High
7/11/2018Needham & Company LLCUpgradeHold ➝ Buy$50.00High
6/27/2018Maxim GroupInitiated CoverageBuy$60.00High
5/24/2018LADENBURG THALM/SH SHInitiated CoverageBuy$90.00Low
5/8/2018Roth CapitalInitiated CoverageBuy$60.00Low
5/7/2018HC WainwrightInitiated CoverageBuy$50.00High
10/24/2017GuggenheimInitiated CoverageBuy$60.00N/A
8/16/2017HC WainwrightSet Price TargetBuy$140.00High
8/7/2017Roth CapitalSet Price TargetBuy$90.00Medium
7/10/2017Roth CapitalInitiated CoverageBuy ➝ Buy$85.00High
5/30/2017AegisReiterated RatingBuyMedium
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2021
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2021
  • 10 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/26/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2022
  • 11 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/26/2022
  • 3 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2022

Current Sentiment

  • 3 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

SCYNEXIS logo
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Read More

Today's Range

Now: $1.90
Low: $1.83
High: $1.91

50 Day Range

MA: $3.14
Low: $1.87
High: $5.05

52 Week Range

Now: $1.90
Low: $1.81
High: $10.25

Volume

148,499 shs

Average Volume

281,910 shs

Market Capitalization

$61.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04

Frequently Asked Questions

What sell-side analysts currently cover shares of SCYNEXIS?

The following Wall Street sell-side analysts have issued research reports on SCYNEXIS in the last year: Aegis, Brookline Capital Management, HC Wainwright, StockNews.com, and Zacks Investment Research.
View the latest analyst ratings for SCYX.

What is the current price target for SCYNEXIS?

0 Wall Street analysts have set twelve-month price targets for SCYNEXIS in the last year. Their average twelve-month price target is $21.50, suggesting a possible upside of 1,031.6%.
View the latest price targets for SCYX.

What is the current consensus analyst rating for SCYNEXIS?

SCYNEXIS currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SCYX will outperform the market and that investors should add to their positions of SCYNEXIS.
View the latest ratings for SCYX.

How do I contact SCYNEXIS's investor relations team?

SCYNEXIS's physical mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company's listed phone number is (201) 884-5485 and its investor relations email address is [email protected] The official website for SCYNEXIS is www.scynexis.com. Learn More about contacing SCYNEXIS investor relations.